GIANT Protocol Raises $5 Million Seed Round Led by CoinFund
16.12.2021 19:30:00 EET | Business Wire | Press release
GIANT Protocol, a leading-edge web3 protocol to decentralize and democratize access to the internet and financial services, is delighted to announce it has raised USD $5 million in a seed funding round led by pioneer blockchain-focused investment firm, CoinFund, with additional participation from other tier one blockchain investors including Blockchange, Gumi Cryptos, Entheos Ventures, Argonautic Ventures, Bronco Fund. The round was oversubscribed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005703/en/
GIANT Protocol Team: Left to Right: Merijn Terheggen COO and Co Founder (left), Suruchi Gupta CEO and Founder (center), Jinesh Doshi, Founding Engineer (right) (Photo: Business Wire)
GIANT (Global Internet Access Network Token) Protocol was founded with the objective to launch a decentralized connectivity economy that can address multiple challenges in the telecom industry. The tokenized bandwidth platform will enable anyone with a mobile phone to access the internet and earn rewards based on their connectivity. GIANT Protocol is in an advanced stage of development with an experienced founding team and a well-established network in the telecom sector.
Suruchi Gupta, Co-Founder and CEO of GIANT, commented "At GIANT, we believe internet access is a basic human right and that an Internet that works for everyone can only be built together. We are at the start of our journey, but we are honoured to have received support from tier one investors who fundamentally understand the problem we are solving with GIANT.”
Jake Brukhman, Founder and CEO CoinFund, said “Telco networks have historically been functionally local, yet our lives have become more international and interconnected. Customers are looking for better telecom services experience all over the World. GIANT is moving the world forward by establishing a new global connectivity economy.”
He added: “As a strategic fund, CoinFund is passionate about being the best partner to early-stage blockchain companies. Suruchi is a rising star in the world of technology and she is also working with some of the most seasoned and respected technology leaders in the industry to bring this idea into a practical utility the world over. GIANT has uniquely pledged to convert bandwidth into a digital asset that can be used as a currency and we are pleased to support this innovative team as they continue to develop their Global Internet Access Network Token.”
As part of GIANT’s development, the project has also hired a world-class team of executives hailing from Juniper, Salesforce, HackerOne, Roku, Mobile365, and others. The team has collectively raised $200M+ in the past and has generated $10B+ in value.
Merijn Terheggen, Co-Founder and COO, has extensive experience at building startups. Before joining GIANT as a Co-Founder, Merijn Terheggen cofounded HackerOne and served as its CEO. HackerOne is the leading and still rapidly growing bug bounty platform that has raised $110M in funding, has about 350 employees, and has 2 million hackers that have found and reported hundreds of thousands of serious security vulnerabilities in thousands of large companies, governments, and banks.
Merijn Terheggen, commented: “HackerOne was created from a desire to unite people working on security and unlock the creativity and ingenuity of those trying to get around obstacles. The key for us had always been about community and collaboration, and rewarding creativity and merits. GIANT is taking this philosophy to a whole new level by leveraging blockchain. Where HackerOne aims to empower the world to build a safer internet, GIANT expands this mission by aiming to empower the world to build the digital infrastructure that humanity will need in the coming decades. And of course this infrastructure is decentralized, democratized, accessible to anyone, and owned by everyone. It is an honour to work with Suruchi and the team on this mission.”
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005703/en/
Contact information
Rachel McHugh
Rachel@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom